In international news from the UK and Europe two significant approvals have recently taken place relating to the treatment of hepatitis C. While Australia still waits for access to the latest treatments the first article talks about access to Sovaldi (sofosbuvir) through the NHS in the UK and the second being the European Commission marketing approval of Viekirax plus Exviera, yet to be submitted in Australia.
Treatments for hepatitis C get provisional backing for NHS use."Gilead Sciences' clinically proven hepatitis C drug Sovaldi has been recommended in final draft guidance from the National Institute for Health and Care Excellence (NICE). The provisional recommendation has endorsed the therapy in combination with pegylated interferon and ribavirin in patients with hepatitis C genotypes 1, 3, 4, 5 and 6," Read this article now.
HCV treatment regimen approved by European Commission
"The European Commission granted marketing authorizations for Viekirax plus Exviera, with or without ribavirin, for the treatment of chronic hepatitis C genotype 1 and 4 infection, according to a press release." Read this article now.